<DOC>
	<DOCNO>NCT01441414</DOCNO>
	<brief_summary>To evaluate combination PF-04856884 ( CVX-060 ) combination Axitinib ( AG-013736 ) patient receive one prior systemic regimen metastatic renal cell carcinoma ( mRCC ) vs. axitinib alone .</brief_summary>
	<brief_title>PF-04856884 ( CVX-060 ) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description>The study prematurely discontinue 06Nov2012 due tolerability finding patient treat Part I study prompt Sponsor re-evaluate strategic development program . An unexpected frequency arterial thrombotic event ( ATEs ) venous thrombotic event ( VTEs ) report patient treated Part I .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Adult male female patient histologically cytologically confirm renal cell cancer ( RCC ) component clear cell subtype evidence metastasis Evidence unidimensionally measurable disease Prior therapy : Part I : Having receive 1 3 prior systemic regimen treatment mRCC Part II : Evidence disease progression follow 1 prior regimen administer 1st line therapy mRCC . The prior regimen must contain one following : VEGFR2 tyrosine kinase inhibitor ( TKI ) anti VEGF [ Vascular Endothelial Growth Factor ] compound , bevacizumab adequate bone marrow , liver renal function Part I : Intolerant prior AG 013736 therapy prior treatment compound contain core platform antibody PF 04856884 Part II : Prior AG 013736 therapy , one systemic firstline regimen treatment mRCC prior treatment compound contain core platform antibody PF 04856884 major surgery &lt; 4 week radiation therapy &lt; 2 week prior start therapy clinically significant gastrointestinal abnormality current use anticipate need drug know potent CYP3A4 inhibitor drug know CYP3A4 CYP1A2 inducer history bleed diathesis coagulopathy Grade 3 great hemorrhage cause &lt; 4 week prior screen ; hemoptysis &gt; Â½ teaspoon blood per day within 2 week prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>CVX-060</keyword>
	<keyword>PF-04856884</keyword>
	<keyword>AG-013736</keyword>
	<keyword>axitinib</keyword>
	<keyword>mRCC</keyword>
	<keyword>metastatic renal cell cancer</keyword>
	<keyword>second line</keyword>
	<keyword>anti-angiogenic</keyword>
	<keyword>Ang-2</keyword>
</DOC>